Skip to main content

Table 9 The scores of SF-36 in the 12-month intervention period

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group \( \overline{x}\pm S \) t P
The treatment group 66.87 ± 6.45 −0.781 0.435
The control group 66.55 ± 6.08